Skip to main content

11 publications

Name Date Type Actions

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

15/04/2021 Public releases

Q1 sales: €85.8M

Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.

19/04/2016 Public releases

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.

21/01/2021 Public releases

2014 sales up 5.2% to €315.3 million

The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014.

22/01/2015 Public releases

2015 sales up 8.7% to €342.6 million

The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.

08/02/2016 Public releases

Q1 2015 sales show solid growth at €81.3 million (up +11.0%)

Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014.

14/04/2015 Public releases

September 2015 year-to-date sales up 8.7% to €251.8 million

Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.

22/10/2015 Public releases

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

30/07/2015 Public releases

2015 results sales of reference products up 9.4% ebit up 10.3%

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

21/03/2016 Public releases

September 2016 year-to-date sales: €257.5 million a 4.8% organic growth

Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. 

18/10/2016 Public releases